Skip to main content

Inpharmatica and Galapagos Genomics Sign Drug Discovery Collaboration

NEW YORK, April 29 - Inpharmatica and Galapagos Genomics have agreed to collaborate on a drug discovery project using Inpharmatica's chemogenomics technology and Galapagos' adenoviral expression platform, the companies said today.

 

Under the agreement, Galapagos, of Mechelen, Belgiumwill provide Inpharmatica with targets for internal disease programs, which Inpharmatica, of London, will evaluate using PharmaCarta, its chemogenomics technology. Galapagos will also provide Inpharmatica acces to its PhenoSelect adenoviral expression platform for validation in-house some of the nuclear receptors that Inpharmatica has discovered.

 

The companies did not disclose the financial terms of the agreement.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.